[ad_1]
-
Galderma, the pure-play dermatology category leader, announces its intention to explore opportunities to build its fifth manufacturing plant in Singapore
-
Supported by the Singapore Economic Development Board, the new facility is expected to increase Galderma’s manufacturing capacity by up to 350 million units per year, in response to continuing demand for premium science-based products in the Dermo-cosmetics sector
Reaffirming its bold ambition to become the leading dermatology company in the world, Galderma today announced its intention to expand its manufacturing and innovation footprint in the Asia-Pacific region, with support from the Singapore Economic Development Board. Galderma intends to explore opportunities to build a fifth manufacturing plant with a high degree of digitalization and automation in Singapore in response to growing consumer demand and to support long-term sustainable growth over the coming years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221012005570/en/
Mr. Tan Kong Hwee, Executive Vice President of the Singapore Economic Development Board (EDB) and Flemming Ørnskov, MD, MPH, Chief Executive Officer of Galderma (Photo: Galderma)
The announcement comes as part of…
Full story available on Benzinga.com
[ad_2]
Source link
